Skip to main navigation

Skip to content

Side Menu

About Us
Our Platform
Our Products
Our Programs
Patients and Physicians
Inside Seres
Open Positions
Investors and News
Contact Us

Press Releases

Seres' news, events and other information can be found throughout the pages below.

Investor Relations

Stock Information
News and Events
- Press Releases
- Events & Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Shareholder Services

Press Releases

Keyword Search

Year

Jun 02, 2023

Seres Therapeutics to Present at Jefferies Healthcare Conference

May 30, 2023

Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™

May 10, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 09, 2023

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

May 09, 2023

Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

May 08, 2023

Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting

May 05, 2023

Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023

Apr 27, 2023

Seres Therapeutics Announces $250 Million Debt Financing with Oaktree

Apr 26, 2023

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™ (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

Apr 07, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Shareholder Tools

RSS Feeds
E-mail Alerts
Print

© 2023 Seres Therapeutics.

Footer Left Menu

Privacy Policy
Terms of Use

Follow us on Linkedin
Follow us on Twitter
Follow us on Facebook